CA
NZ
UK
AU
IND
US
Incyte (Nasdaq:INCY) reported second-quarter results on 28 July. Total revenues reached $1.67 billion, up 38% year over year, and management lifted full-year net product sales guidance to $5.13–$5.26 billion from $4.77–$4.94 billion. "Our second quarter was marked by broad-based sales growth, continued pipeline progress …
Elanco Animal Health (NYSE:ELAN) closed at $26.37, down nine cents, or 0.34%, on volume of about 5.2 million shares. That is a shrug of a session, and an unusually calm one, given what happens next. The company reports second-quarter results on Wednesday, 5 August, …
Lilly (NYSE:LLY) reports second-quarter 2026 results on August 5 and hosts a conference call at 10 a.m. Eastern. Investors already know roughly what the injectables will do. What they do not know is whether the company's oral GLP-1, Foundayo (orforglipron), is a slow starter …
Exelixis (Nasdaq:EXEL) closed at $53.03 at last closing, down $2.94 or 5.25%, on roughly 3.0 million shares against a recent daily average nearer two million. The size of the fall matches the move flagged in early commentary. Its cause does not match the usual …
GE HealthCare (Nasdaq:GEHC) shares closed at $68.02 at last closing, down 2.75% on the day and 5.4% below the $71.90 close reached on 29 July, when second-quarter results lifted the stock 12.15% on volume of 15.3 million shares, several times its recent daily average. …
The second-quarter report Edwards Lifesciences (NYSE:EW) filed at last closing was, on its face, the cleanest print the structural heart company has produced in some time. Sales of $1.74 billion rose 13.6% as reported and 12.5% in constant currency against $1.53 billion a year …
Biogen (Nasdaq:BIIB)'s investment case has rested on one question since Tecfidera lost exclusivity: could new medicines grow faster than old ones decay? On 29 July the company reported that the crossover had arrived. Its growth portfolio delivered $1.06 billion of second-quarterRevenue, up 24% year …
BioMarin (Nasdaq:BMRN) closed its all-cash acquisition of Amicus Therapeutics at last closing at $14.50 a share, about $4.8bn of equity value and $5.32bn of total consideration once equity awards, transaction expenses and repaid Amicus debt are counted. It brings in Galafold for Fabry disease …
BioNTech (Nasdaq:BNTX) closed at $90.58, down 2.44% on the session and about 18% over the past twelve months. The German biotech that co-developed Comirnaty with Pfizer now books so littleVaccineincome that its quarterly revenue is smaller than the quarterly cost of its research organization. …
Boston Scientific (NYSE:BSX) delivered better numbers than it had promised for the June quarter and lowered its full-year outlook in the same release. Net sales of $5.442 billion on 29 July rose 7.5% as reported and 7.0% organically. AdjustedEarningsof $0.86 a share topped the …
Please wait processing your request...